GO
Loading...

Pfizer Inc

More

  • Dems press blocks on corporate tax inversions plans Tuesday, 22 Jul 2014 | 8:35 AM ET

    Democrats, searching for campaign issues before November's congressional elections, have jumped on inversions, and several of them have offered bills that would curb the deals.

  • July 18- Catalent Inc, controlled by Blackstone Group LP, said it expects its initial public offering to be priced between $19 and $22 per share, valuing the company at about $2.57 billion at the top end. The company's major customers include Pfizer Inc, Johnson& Johnson, GlaxoSmithKline Plc, Merck& Co Inc and Novartis AG.

  • July 17- Shire Plc and U.S. drugmaker Abbvie Inc plan to announce a $53 billion merger as soon as Friday morning, two people said on Thursday. Dublin- based Shire, which sells drugs for rare diseases, said earlier this week it was ready to recommend a deal to shareholders after AbbVie increased its offer.

  • July 17- Shire Plc and U.S. drugmaker Abbvie Inc plan to announce a $53 billion merger as soon as Friday morning, two people said on Thursday. Dublin- based Shire, which sells drugs for rare diseases, said earlier this week it was ready to recommend a deal to shareholders after AbbVie increased its offer.

  • Midday Glance: Pharmaceuticals companies Wednesday, 16 Jul 2014 | 2:54 PM ET

    Baxter International Inc. fell$. 23 or. 3 percent, to $76.53. Bristol-Myers Squibb Co. fell$. 08 or. 2 percent, to $48.63. Hospira fell$. 17 or. 3 percent, to $50.58.

  • Most active New York Stock Exchange-traded stocks Wednesday, 16 Jul 2014 | 2:54 PM ET

    NEW YORK— A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:. AbbVie fell. 6 percent to $53.14 with 13,607,100 shares traded. Advanced Micro Devices Inc. rose 2.7 percent to $4.65 with 46,059,000 shares traded.

  • ZURICH, July 16- Roche's experimental drug crenezumab failed to delay a decline in thinking and memory skills in people with Alzheimer's disease, a result likely to bolster a growing belief that drugs need to be given in earlier stages of the disease to show a benefit.

  • Roche Alzheimer's drug fails main goals in mid-stage study Wednesday, 16 Jul 2014 | 11:30 AM ET

    ZURICH, July 16- Roche said its experimental Alzheimer's drug failed to meet its main goals in a mid-stage study, a result likely to bolster the belief that drugs need to be given in earlier stages of the disease to slow patients' decline.

  • Early Glance: Pharmaceuticals companies Wednesday, 16 Jul 2014 | 11:11 AM ET

    Baxter International Inc. fell$. 09 or. 1 percent, to $76.67. Bristol-Myers Squibb Co. rose$. 17 or. 3 percent, to $48.88. Hospira rose$. 04 or. 1 percent, to $50.79.

  • Genentech Alzheimer's drug misses goals in studies Wednesday, 16 Jul 2014 | 11:00 AM ET

    Jeffrey Cummings of the Cleveland Clinic said none of the deaths seemed due to the drug and pneumonia occurred at a rate to be expected in older people. Results were revealed Wednesday at the Alzheimer's Association International Conference in Copenhagen.

  • July 16- The Obama administration urged Congress on Wednesday to act to stem what it described as a growing trend in which U.S. companies move their headquarters abroad to reduce their U.S. tax bills. "Congress should enact legislation immediately," Treasury Secretary Jack Lew told a business conference in New York hosted by cable television channel CNBC.

  • July 16- Pfizer Inc said a once-weekly dose of its drug, already approved for on-demand treatment of a blood clotting disorder, reduced bleeding rates in patients in a late-stage study.

  • Midday Glance: Pharmaceuticals companies Monday, 14 Jul 2014 | 1:29 PM ET

    Baxter International Inc. rose$. 03 or percent, to $76.62. Bristol-Myers Squibb Co. rose$. 28 or. 6 percent, to $48.90. Hospira rose$. 43 or. 8 percent, to $51.25.

  • Early Glance: Pharmaceuticals companies Monday, 14 Jul 2014 | 10:47 AM ET

    Baxter International Inc. rose$. 20 or. 3 percent, to $76.79. Bristol-Myers Squibb Co. fell$. 04 or. 1 percent, to $48.58. Hospira fell$. 03 or percent, to $50.80.

  • FACTBOX-M&A frenzy transforming global pharma Monday, 14 Jul 2014 | 9:27 AM ET

    July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.

  • *AbbVie raises bid to 53.20/ share from 51.15. *Bid comprises 24.44 stg cash and 0.8960 new AbbVie shares. LONDON, July 14- London- listed drugmaker Shire Plc succumbed to an increased 31 billion pounds takeover offer from Abbvie Inc on Monday, signaling the conclusion to a long-running courtship largely motivated by tax.

  • UK to demand job assurances in foreign takeovers Sunday, 13 Jul 2014 | 7:36 AM ET
    UK Business Secretary Vince Cable

    Britain is to set out proposals to force foreign buyers of key UK companies to make binding commitments to secure jobs and research budgets.

  • Allergan to shareholders: Ignore Pershing Square Friday, 11 Jul 2014 | 6:31 PM ET
    A vial of Allergan’s Botox is arranged next to boxes for a photograph at a doctor's office in Manhattan Beach, Calif.

    Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.

  • Midday Glance: Pharmaceuticals companies Friday, 11 Jul 2014 | 1:37 PM ET

    Baxter International Inc. fell$. 54 or. 7 percent, to $76.21. Bristol-Myers Squibb Co. fell$. 07 or. 1 percent, to $48.44. Hospira fell$. 34 or. 7 percent, to $50.72.

  • The Alzheimer's epidemic: Where we stand Friday, 11 Jul 2014 | 11:45 AM ET

    Although treatments for Alzheimer's have struggled, drugmakers are still working in the space, with 67 medicines currently in development.